Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 6/2007

01-08-2007 | Original Paper

The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies

Authors: David G. Cox, Dwayne Deer, Qun Guo, Shelley S. Tworoger, Susan E. Hankinson, David J. Hunter, Immaculata De Vivo

Published in: Cancer Causes & Control | Issue 6/2007

Login to get access

Abstract

Candidate gene association studies to detect breast cancer susceptibility loci have yielded few positive associations. Therefore, it is more likely that variants in many genes along related biological pathways combine to influence breast cancer risk. A strong candidate pathway is that of p53-mediated cell-cycle control, DNA repair, and apoptosis. The two major proteins along this pathway are p53 and its negative regulator MDM2. Functional polymorphisms in both genes have been identified. The -309 SNP in MDM2 is associated with increased MDM2 transcription. The Arg72Pro polymorphism of p53 alters the transcription of p53 target genes and modifies the apoptotic potential of cells. Both polymorphisms have been studied with respect to breast cancer risk, with inconclusive results. We have genotyped both polymorphisms in the breast cancer cases and controls nested within the Nurses’ Health Study and Nurses’ Health Study II. Neither SNP is independently associated with overall breast cancer risk. Some indication of gene-by-gene interaction was observed; however, no consistent direction of interaction was apparent.
Literature
1.
Freedman DA, Wu L, Levine AJ (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55:96–107PubMedCrossRef
2.
Picksley SM, Lane DP (1993) The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15:689–690PubMedCrossRef
3.
Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ (1998) Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. Embo J 17:554–564PubMedCrossRef
4.
Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299PubMedCrossRef
5.
6.
Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365PubMedCrossRef
7.
Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196–199PubMedCrossRef
8.
Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092–1100PubMed
9.
Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66:5104–5110PubMedCrossRef
10.
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602PubMedCrossRef
11.
Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10:307–311PubMedCrossRef
12.
Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, Gorodinskaya VM, Pozharisski KM, Berstein LM, Hanson KP, Togo AV, Imyanitov EN (2003) Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 103:431–433PubMedCrossRef
13.
Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105–112PubMed
14.
Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R, Runnebaum IB (1998) p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 18:2095–2099PubMed
15.
Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313–1316PubMedCrossRef
16.
Campbell IG, Eccles DM, Choong DY (2005) No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240(2):195–197
17.
Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Jin G, Liu J, Wei Q, Shen H (2005) Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 240(2):261–267
18.
Wilkening S, Bermejo JL, Burwinkel B, Klaes R, Bartram CR, Meindl A, Bugert P, Schmutzler RK, Wappenschmidt B, Untch M, Hemminki K, Forsti A (2006) The single nucleotide polymorphism IVS1 + 309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res 66:646–648PubMedCrossRef
19.
Millikan RC, Heard K, Winkel S, Hill EJ, Massa B, Mayes L, Williams P, Holston R, Conway K, Edmiston S, de Cotret AR (2006) No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 15:175–177PubMedCrossRef
20.
Copson ER, White HE, Blaydes JP, Robinson DO, Johnson PW, Eccles DM (2006) Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer 6:80PubMedCrossRef
21.
Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98:911–919PubMedCrossRef
22.
Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90:1292–1299PubMedCrossRef
23.
Baer HJ, Rich-Edwards JW, Colditz GA, Hunter DJ, Willett WC, Michels KB (2006) Adult height, age at attained height, and incidence of breast cancer in premenopausal women. Int J Cancer 119(9):2231–2235
24.
Gauderman WJ (2002) Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 21:35–50PubMedCrossRef
25.
Jin S, Levine AJ (2001) The p53 functional circuit. J Cell Sci 114:4139–4140PubMed
26.
Mayer C, Grummt I (2005) Cellular stress and nucleolar function. Cell Cycle 4:1036–1038PubMed
27.
Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203–206CrossRef
28.
Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206–208PubMedCrossRef
Metadata
Title
The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies
Authors
David G. Cox
Dwayne Deer
Qun Guo
Shelley S. Tworoger
Susan E. Hankinson
David J. Hunter
Immaculata De Vivo
Publication date
01-08-2007
Publisher
Kluwer Academic Publishers
Published in
Cancer Causes & Control / Issue 6/2007
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9004-x

Other articles of this Issue 6/2007

Cancer Causes & Control 6/2007 Go to the issue

Original Paper

Age-related differences in factors associated with smoking initiation

Original Paper

Body mass index, physical activity and the risk of pancreatic cancer in relation to smoking status and history of diabetes: a large-scale population-based cohort study in Japan–The JPHC study

Original Paper

Birthweight by gestational age and childhood cancer

Original Paper

Human papillomavirus vaccine: knowledge and attitudes in two Appalachian Kentucky counties

Original Paper

Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences

Original Paper

Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and the risk of primary Hepatocellular Carcinoma (HCC) in a Chinese population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits